Core Viewpoint - Beijing's new measures aim to support the high-quality development of innovative pharmaceuticals and medical devices through a comprehensive policy framework that enhances the entire industry chain from research to application [1] Group 1: Policy Measures - The "Measures 2025" introduces 32 new initiatives to strengthen support for innovative drug and medical device research, production, review, and use [1] - The measures are based on the evaluation of the previous year's policies and focus on optimizing clinical trials, review processes, and production logistics [1] Group 2: Review and Approval Efficiency - The approval time for innovative drug clinical trials will be reduced from 60 working days to 30, with an expansion of pilot varieties to include medical devices [2] - The review time for supplementary drug applications will be cut from 200 working days to 60, enhancing the efficiency of drug production technology upgrades [2][3] Group 3: Artificial Intelligence Integration - The measures encourage the establishment of AI research centers in Beijing to enhance data integration and promote AI applications in drug discovery and clinical research [4] - A large model evaluation system for AI applications in various medical fields will be developed, supporting at least 10 application scenarios [5] Group 4: Biobank Development - The establishment of high-quality biobanks is emphasized as crucial for the rapid industrialization of significant research findings, particularly in precision medicine [6] - Plans are in place to build automated intelligent biobanks focused on specific diseases, enhancing the availability of high-quality sample data for research [6][7]